XHANCE Has Continued to Demonstrate a Consistent Safety Profile¹

Adverse events occurring in ≥3% of patients and more common than placebo

Adverse event, n (%)	EDS-placebo BID (n=187)	XHANCE 186 mcg BID (n=184)	XHANCE 372 mcg BID (n=183)
Adverse event, n (%)	EDS-placebo BID (n=187)	XHANCE 186 mcg BID (n=184)	XHANCE 372 mcg BID (n=183)	Epistaxis	1 (0.5)	9 (4.9)	20 (10.9)
Headache	7 (3.7)	4 (2.2)	10 (5.5)
Nasopharyngitis	8 (4.3)	9 (4.9)	7 (3.8)

BID=twice daily.

Adverse event, n (%)	EDS-placebo BID (n=161)	XHANCE 186 mcg BID (n=160)	XHANCE 372 mcg BID (n=161)
Adverse event, n (%)	EDS-placebo BID (n=161)	XHANCE 186 mcg BID (n=160)	XHANCE 372 mcg BID (n=161)	Epistaxis*	4 (2.5)	19 (11.9)	16 (9.9)
Nasopharyngitis	8 (5.0)	3 (1.9)	12 (7.5)
Nasal septal ulceration^†	3 (1.9)	11 (6.9)	12 (7.5)
Nasal congestion	6 (3.7)	7 (4.4)	9 (5.6)
Acute sinusitis	6 (3.7)	7 (4.4)	8 (5.0)
Headache	5 (3.1)	8 (5.0)	6 (3.7)
Pharyngitis	2 (1.2)	2 (1.3)	5 (3.1)
Nasal mucosal ulceration	2 (1.3)	6 (3.8)	4 (2.5)
Nasal mucosal erythema	6 (3.7)	9 (5.6)	8 (5.0)
Nasal septal erythema	3 (1.9)	6 (3.8)	7 (4.3)

*Includes spontaneous adverse reaction reports.

^†Includes ulcerations and erosions.

Explore More

Show your patients how to  administer XHANCE

Go to Dosing

Find options and tools for access and affordability

Discover Tools

+

Reference:

Full Prescribing Information for XHANCE (fluticasone propionate). OptiNose US, Inc.; 2024.

INDICATIONS

XHANCE is a corticosteroid indicated for the treatment of chronic rhinosinusitis with or without nasal polyps in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:
Hypersensitivity to any ingredient in XHANCE.

WARNINGS AND PRECAUTIONS:

Local nasal adverse reactions, including epistaxis, erosion, ulceration, septal perforation, Candida albicans infection, and impaired wound healing, can occur. Monitor patients periodically for signs of possible changes on the nasal mucosa. Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma until healing has occurred.
Glaucoma and cataracts may occur with long-term use. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use XHANCE long-term.
Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after administration of fluticasone propionate. Discontinue XHANCE if such reactions occur.
Immunosuppression and infections can occur, including potential increased susceptibility to or worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infection; ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients.
Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue XHANCE slowly.
Assess for decrease in bone mineral density initially and periodically thereafter.

ADVERSE REACTIONS:

Chronic rhinosinusitis without nasal polyps: The most common adverse reactions (incidence ≥ 3%) are epistaxis, headache, and nasopharyngitis.
Chronic rhinosinusitis with nasal polyps: The most common adverse reactions (incidence ≥ 3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.

DRUG INTERACTIONS:
Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects.

USE IN SPECIFIC POPULATIONS:
Hepatic impairment. Monitor patients for signs of increased drug exposure.

Please see Full Prescribing Information pdf opensfull Prescribing Information, including Instructions for Use.

Reference:

Full Prescribing Information for XHANCE (fluticasone propionate). OptiNose US, Inc.; 2024.